We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cellular Dynamics Raises $40.6 M in its Series B Equity Round

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cellular Dynamics Raises $40.6 M in its Series B Equity Round"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

CDI also plans to use the proceeds to rapidly expand its commercial organization to meet the growing demand for these iPSC-based products. CDI has raised a total of $70 million since 2004. 

“CDI has now secured the highest-level of funding in this new industry,” said Robert Palay, the company’s Chairman and Chief Executive Officer. “We have strong demand from pharmaceutical companies for live heart cells derived from iPSCs because the high purity and quality of our cells result in more accurate preclinical drug testing. Prior to our product introduction, new drugs were tested primarily on either human tissue cells from cadavers, cells derived from tumors, or animal cells, none of which accurately mirror what happens in a live human body.  We believe access to iCell Cardiomyocytes will help speed the discovery of safer and more effective medicines.” 

CDI will also apply the new funding toward expansion of its product lines beyond the current iCell Cardiomyocytes product offering. ”We intend to launch liver, nerve, and blood vessel cell products over the next 18 months,” said Chris Parker, CDI’s Chief Commercial Officer.

CDI’s breakthrough is in the production process, which can produce large quantities of human heart cells while fully maintaining their purity, quality and consistency. The company’s iCell Cardiomyocytes product line is the first commercial product based on stem cells grown from adult tissue using CDI Founder James A. Thomson’s iPSC technology.

CDI grows its fully pluripotent stem cell lines from individual skin or blood samples from adults.  “Our iPSC approach gives our pharmaceutical customers the opportunity to test their drugs’ specific effects on different people’s heart cells, allowing them to look at the effect of drugs on people based on factors such as gender, heritage and other biological differences," added Parker. The company’s iPSC technology isolates and cultures skin or blood cells from human donors and then coaxes them to turn back their developmental clock and become iPSCs, which then can be further directed to morph into any of the human body’s 200+ cell types.

“Today, iCell Cardiomyoctyes help pharmaceutical companies speed the discovery of safer, more effective drugs.  Our vision is to one day manufacture personal stem cell lines for any individual, and to grow large quantities of that person’s heart and other cells for their own bank of cells.  I can foresee a day in the not-so-distant future when doctors will be testing medicines for safety and effectiveness on your own cells before giving you a prescription.  CDI is working towards the day when such personalized drug testing leads to safer, more effective treatments,” said Palay.